Monopar Therapeutics (MNPR) Income from Continuing Operations (2017 - 2026)
Monopar Therapeutics (MNPR) posted Income from Continuing Operations of 4269637.0 for Q3 2025, down 65.64% sequentially from 2577616.0 in Q2 2025, and down 189.36% YoY from 4778154.49 in Q3 2024.
Monopar Therapeutics (MNPR) Income from Continuing Operations (2017 - 2026) Analysis & Trends
Monopar Therapeutics has reported Income from Continuing Operations for 9 years, with the latest figure at 4269637.0 in Q3 2025.
- Quarterly Income from Continuing Operations fell 189.36% year-over-year to 4269637.0 in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 11544286.0 (down 66.83% YoY) and the FY2025 annual result came in at 13716095.0, up 11.45% from the prior year.
- Income from Continuing Operations declined to 4269637.0 in Q3 2025 per MNPR's latest filing, from 2577616.0 in the prior quarter.
- Over five years, Income from Continuing Operations peaked at 1475558.0 in Q3 2024 and troughed at 13420480.0 in Q4 2022.
- A 5-year average of 3518655.59 and a median of 2459020.0 in 2021 frame the typical range for Income from Continuing Operations.
- The sharpest annual moves came in 2024 and 2025: Income from Continuing Operations jumped 31.6% in 2024, then tumbled 189.36% in 2025.
- Over 5 years, Income from Continuing Operations stood at 10401402.0 in 2021, then slipped by 29.03% to 13420480.0 in 2022, then soared by 85.44% to 1953734.0 in 2023, then grew by 24.47% to 1475558.0 in 2024, then sank by 189.36% to 4269637.0 in 2025.
- According to Business Quant data, Income from Continuing Operations over the past three periods registered 4269637.0, 2577616.0, and 3221475.0 for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 482.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,096.02 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Monopar Therapeutics | 965.64 Mn | 912.88 Mn | - | -5.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -5.57 Mn |
| Sep 30, 2025 | -4.27 Mn |
| Jun 30, 2025 | -2.58 Mn |
| Mar 31, 2025 | -3.22 Mn |
| Sep 30, 2024 | -1.48 Mn |
| Jun 30, 2024 | -1.79 Mn |
| Mar 31, 2024 | -1.70 Mn |
| Sep 30, 2023 | -1.95 Mn |
| Jun 30, 2023 | -2.35 Mn |
| Mar 31, 2023 | -2.49 Mn |
| Dec 31, 2022 | -13.42 Mn |
| Sep 30, 2022 | -2.41 Mn |
| Jun 30, 2022 | -2.85 Mn |
| Mar 31, 2022 | -2.46 Mn |
| Dec 31, 2021 | -10.40 Mn |
| Sep 30, 2021 | -2.46 Mn |
| Jun 30, 2021 | -2.09 Mn |
| Mar 31, 2021 | -1.89 Mn |
| Dec 31, 2020 | -7.48 Mn |
| Sep 30, 2020 | -1.65 Mn |